Arvinas, Inc. (NASDAQ:ARVN)
| Market Cap | 441.19M-39.7% |
| Revenue (ttm) | 275.30M-11.8% |
| Net Income | -9.50M+83.8% |
| EPS | -0.18+77.8% |
| Shares Out | 65.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 256,958.935 |
| Open | 6.57 |
| Previous Close | 6.76 |
| Day's Range | 6.49 - 6.80 |
| 52-Week Range | 6.33 - 14.51 |
| Beta | 1.80 |
| Analysts | Buy |
| Price Target | 14.00(+107.49%) |
| Earnings Date | Feb 23, 2027 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ARVN
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating ARVN in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 23, 2027Earnings report
$ARVN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ARVN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ARVN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ARVN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ARVN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ARVN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ARVN
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $14.86M |
| IWMiShares Russell 2000 ETF | $10.52M |
| VXFVanguard Extended Market ETF | $5.32M |
| IWNiShares Russell 2000 Value ETF | $3.31M |
| FESMFidelity Enhanced Small Cap ETF | $3.26M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $3.06M |
Estimated from each fund’s disclosed top holdings × AUM
ARVN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ARVN’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: 94 sector peers carry a ranked score; this one has no qualifying buying in the window · sector average 60.3
What’s Behind the Score
News check: Phase 1 data sharing and trial initiation for multiple candidates signal pipeline progress and R&D advancement.